stock sold off - CEO interviewed: Revlimid is still the best drug in its class for treating cancer - the data will speak for itself over time - it will be the standard of care - Cramer says to stick with it
50.21
+89.79%
01/03/08
don't have as much faith in it as before - let's wait for another qtr
49.85
+88.43%
01/14/08
could go to the mid 60's
53.98
+104.04%
01/17/08
goes to 60
55.62
+110.24%
01/22/08
gets back to 60 - but co needs product diversification
52.28
+97.62%
03/27/08
would sell half
60.92
+130.28%
07/09/08
had a good run - would wait for a pullback
70.53
+166.60%
07/30/08
have faith in CEO - has good earnings visibilty thru 2012 - want to own it
Back to Top